Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RIGL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRigel completes $70M acquisition of exclusive global rights to VEPPANU cancer drug
Filed June 17, 2026 · Period ending June 11, 2026 · ~1 min read
Key Changes
-
high
Rigel paid $70M upfront to Arvinas and Pfizer for exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant) after early HSR antitrust clearance.
Item 2.01 verify on EDGAR → -
high
The license grants Rigel sole global control of the drug candidate across its full commercial lifecycle, positioning the company as the only entity developing vepdegestrant worldwide.
Item 2.01 verify on EDGAR →
Summary
Rigel Pharmaceuticals has completed its acquisition of exclusive global rights to VEPPANU (vepdegestrant), a drug candidate previously held by Arvinas and Pfizer. The transaction closed after receiving early termination of the HSR antitrust waiting period, with Rigel paying a $70 million upfront payment to the licensors.
The license is comprehensive, covering development, manufacturing, and commercialization rights worldwide. For investors, this represents a significant strategic expansion of Rigel's pipeline. The company now has sole control of vepdegestrant's development path globally, rather than sharing rights through a partnership or regional arrangement.
The $70M upfront payment is material for a company of Rigel's size and signals management's confidence in the asset's commercial potential. The early HSR clearance suggests regulators saw no competitive concerns with the transaction structure.
Section-by-Section Diff
Event · Item 2.01 — Completion of Acquisition or Disposition of Assets
Item 2.01 — Completion of Acquisition or Disposition of Assets filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the satisfaction of the other closing conditions under the License Agreement, the License Agreement became effective and the transactions contemplated thereby were completed. In connection therewith, the Company paid the Licensors a one-time upfront payment of $70.0 million.
Rigel completed its previously announced license agreement with Arvinas and Pfizer to acquire exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant). The transaction closed after HSR antitrust clearance was granted early, and Rigel paid a $70 million upfront payment to the licensors. This gives Rigel worldwide control of a drug candidate that was in-licensed from the Arvinas-Pfizer partnership.
Added in current filing · verify on EDGAR →
the Licensors granted the Company exclusive, global rights to develop, manufacture and commercialize VEPPANU™ (vepdegestrant) and related products worldwide
The license covers exclusive worldwide rights across the full commercial lifecycle: development, manufacturing, and commercialization of vepdegestrant and related products. This is a comprehensive asset acquisition that positions Rigel as the sole entity controlling this drug candidate globally, rather than a co-development or regional partnership.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify